Takeda Pharmaceutical Competitors

Takeda Pharmaceutical (NYSE:TAK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 9.9% of Novartis shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Novartis pays an annual dividend of $2.01 per share and has a dividend yield of 2.1%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Novartis pays out 38.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Risk and Volatility

Takeda Pharmaceutical has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Novartis has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Novartis' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Takeda Pharmaceutical and Novartis' top-line revenue, earnings per share (EPS) and valuation.

Novartis has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Takeda Pharmaceutical and Novartis, as reported by MarketBeat.

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Novartis has a consensus price target of $114.00, suggesting a potential upside of 19.21%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Takeda Pharmaceutical is more favorable than Novartis.

Summary

Novartis beats Takeda Pharmaceutical on 11 of the 16 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.1%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 1 consecutive years. Takeda Pharmaceutical is clearly the better dividend stock, given its higher yield and lower payout ratio.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Takeda Pharmaceutical and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Merck & Co., Inc., as reported by MarketBeat.com.

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 14.36%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Merck & Co., Inc..

Summary

Merck & Co., Inc. beats Takeda Pharmaceutical on 11 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.1%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Pfizer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Takeda Pharmaceutical and Pfizer's gross revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Pfizer, as reported by MarketBeat.com.

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Pfizer has a consensus price target of $40.0714, suggesting a potential upside of 9.19%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Pfizer.

Summary

Pfizer beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.6%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has raised its dividend for 49 consecutive years. Takeda Pharmaceutical is clearly the better dividend stock, given its higher yield and lower payout ratio.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Abbott Laboratories' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Takeda Pharmaceutical and Abbott Laboratories' gross revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Abbott Laboratories, as reported by MarketBeat.com.

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Abbott Laboratories has a consensus price target of $115.6875, suggesting a potential upside of 3.94%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.7%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. AbbVie pays out 58.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and AbbVie's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Takeda Pharmaceutical and AbbVie's gross revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and AbbVie, as reported by MarketBeat.com.

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. AbbVie has a consensus price target of $112.50, suggesting a potential upside of 1.79%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than AbbVie.

Summary

AbbVie beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Takeda Pharmaceutical and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Eli Lilly and has lower revenue, but higher earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Takeda Pharmaceutical and Eli Lilly and's net margins, return on equity and return on assets.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Eli Lilly and, as reported by MarketBeat.com.

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Eli Lilly and has a consensus price target of $172.2143, suggesting a potential downside of 9.73%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Eli Lilly and.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Eli Lilly and pays an annual dividend of $2.96 per share and has a dividend yield of 1.6%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Eli Lilly and pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has raised its dividend for 1 consecutive years. Takeda Pharmaceutical is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Eli Lilly and beats Takeda Pharmaceutical on 11 of the 18 factors compared between the two stocks.